# CarelonRx

CarelonRx is an Asset Manager based in Morristown, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Morristown, United States
- **Region:** North America
- **Address:** Morristown, NJ, United States
- **Assets under management:** Undisclosed
- **Website:** ingenio-rx.com
- **LinkedIn:** https://www.linkedin.com/company/ingenio-rx

## Regulatory record

- **Reports private funds:** No

## About

CarelonRx is a pharmacy benefit manager focused on people, not just prescriptions. Our expertise aims to improve health outcomes at all stages of healthcare.

## Sectors

- Healthcare Services

## Questions

### What is CarelonRx's scale in terms of membership and prescription volume?

CarelonRx internal data for 2024 reports 17.2 million members and over 360 million prescriptions managed annually. The firm draws on 35 years of pharmacy benefit management experience inherited from its Anthem-era predecessor operations.

### Does CarelonRx participate in specialty pharmacy management?

Yes. CarelonRx integrates specialty pharmacy into its core PBM service model, managing high-cost therapies through negotiated rebates and clinical oversight. The firm disclosed that 44% of its clients had a negative specialty drug trend in 2024, a metric that reflects their ability to offset rising specialty costs.

### Who runs CarelonRx?

CarelonRx does not publicly disclose its leadership team on its primary website, and no named executives were identifiable from available sources as of 2026. The firm operates under the broader Carelon and Elevance Health executive structure, which is led by Elevance Health's CEO.

### Does CarelonRx manage a home-delivery pharmacy?

Yes. CarelonRx offers home-delivery mail-order pharmacy services as part of its integrated PBM platform. This allows the firm to bypass retail pharmacies for maintenance medications, capturing additional margin and controlling fulfillment directly.

### What is CarelonRx's approach to evidence-based formulary design?

CarelonRx emphasizes real-world data and clinical evidence in its coverage decisions. In 2025, the firm published a study analyzing GLP-1 receptor agonists using real-world data to evaluate therapeutic risks and benefits, reflecting its reliance on applied research to guide formulary placement and utilization management.

## Related profiles

- [AMJ Capital](https://altss.com/profile/amj-capital)
- [The Magstim Company](https://altss.com/profile/the-magstim-company-ltd)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/ingeniorx

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology